Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

shutterstock_159488225

New data shows Gilead’s remdesivir “potently inhibited” SARS-CoV-2 in human lung cell cultures

July 10, 2020
Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir

New findings published from researchers at Vanderbilt University Medical Center (VUMC) at the University of North Carolina, as well as …

News
shutterstock_273326141

Gilead acquires 49.9% of Pionyer Therapeutics in potential $1.5bn+ deal

June 24, 2020
Research and Development, Sales and Marketing Gilead, Pionyr, pharma

Gilead has announced its intention to acquire 49.9% of shares in cancer immunotherapy specialist Pionyr Therapeutics with a payment of …

News
gilead-sciences

Gilead to investigate inhaled formulation of promising COVID-19 therapy remdesivir

June 23, 2020
Manufacturing and Production, Research and Development COVID-19, Gilead, remdesivir

Gilead is intent on pushing the applications of its antiviral drug remdesivir after it has shown efficacy in the treatment …

News
remdesivir_ulrich_perrey

EMA could approve Gilead’s streamlined remdesivir application for COVID-19 “within weeks”

June 9, 2020
Manufacturing and Production, Sales and Marketing COVID-19, EU, Gilead, coronavirus, remdesivir

The European Medicines Agency has received the application from Gilead for the first conditional marketing authorisation (CMA) of its antiviral …

News
remdesivir_ulrich_perrey

Australian Taskforce recommends Gilead’s remdesivir for routine use in the country’s COVID-19 patients

June 5, 2020
Medical Communications, Sales and Marketing Australia, COVID-19, Gilead, coronavirus, remdesivir

Australia could be set to follow the decisions of other nations around the world in officially licensing Gilead’s antiviral therapy …

News
remdesivir_ulrich_perrey

India and South Korea approve Gilead’s remdesivir for emergency use against COVID-19

June 3, 2020
Research and Development, Sales and Marketing COVID-19, Gilead, India, coronavirus, remdesivir, south korea

India and South Korea have moved to follow in the footsteps of the US in approving Gilead’s antiviral therapy remdesivir …

News
david_paul_morrisbloomberg

Five-day remdesivir regimen shows promising clinical benefit in COVID-19 patients, Phase 3 data shows

June 2, 2020
Manufacturing and Production, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir

Gilead has unveiled eagerly anticipated new Phase 3 data on the addition of its antiviral therapy remdesivir to standard of …

News
gilead-sciences

Gilead’s magrolimab shows promising responses in untreated myelodysplastic syndrome and acute myeloid leukaemia at ASCO 2020

June 1, 2020
Research and Development, Sales and Marketing ASCO 2020, Cancer, Gilead, leukaemia, magrolimab

Gilead took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to unveil new Phase 1b …

News
shutterstock_243110086

First ever benefit-risk analysis is “favourable” for remdesivir as COVID-19 treatment

May 29, 2020
Medical Communications, Research and Development COVID-19, DSRU, Gilead, coronavirus, pharma, remdesivir

The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s …

News
japan_mhlw

Japan authorises exceptional approval of Gilead’s remdesivir for severe COVID-19

May 12, 2020
Manufacturing and Production, Sales and Marketing COVID-19, Gilead, Japan, coronavirus, pharma, remdesivir

Remdesivir, perhaps the leading hope in the race against COVID-19, has secured approval from Japan’s Ministry of Health, Labour and …

News
gilead-sciences

FDA approves emergency use of Gilead’s remdesivir for hospitalised COVID-19 patients

May 4, 2020
Sales and Marketing COVID-19, FDA, Gilead, coronavirus, remdesivir

Gilead’s antiviral therapy remdesivir has shown tentatively promising efficacy in the race to find an effective treatment for COVID-19, one …

News
top_10_image_2_1

Top Ten most popular articles on Pharmafile.com this week

May 1, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Gilead, UK, coronaviurs

The search for a COVID-19 treatment has ramped up this week, with two new studies detailing the efficacy of Gilead’s …

News
gilead-speeds-manufacture-of-experimental-covid-19-drug-biospace-4-5-20-495x350

Two studies reveal “positive” data for Gilead’s remdesivir in hospitalised COVID-19 patients

April 30, 2020
Research and Development COVID-19, Gilead, coronavirus, remdesivir

The first findings of two new studies have been revealed detailing the efficacy of Gilead’s antiviral therapy remdesivir in the …

News
gilead-sciences

Leading COVID-19 hope remdesivir fails to provide clinical benefit in first randomised trial

April 24, 2020
Medical Communications, Research and Development COVID-19, Gilead, coronavirus, pharma, remdesivir

Gilead’s remdesivir, which has been hailed as one of the few truly promising treatments for COVID-19 at this early stage …

News
800px-rhesus_macaque_macaca_mulatta_in_kinnarsani_ws_ap_w_img_5792

Gilead’s remdesivir significantly reduces COVID-19 symptoms in rhesus monkeys in NIH trial

April 20, 2020
Business Services, Medical Communications, Sales and Marketing COVID-19, Gilead, National Institutes of Health, coronavirus, remdesivir

A study from the National Institutes of Health has shed more light on the efficacy of Gilead’s promising antiviral therapy …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025